TY - JOUR
T1 - Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients
AU - Piscitelli, Stephen C.
AU - Figg, William D.
AU - Hahn, Barbara
AU - Kelly, Grace
AU - Thomas, Steven
AU - Walker, Robert E.
PY - 1997/12
Y1 - 1997/12
N2 - The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (± standard deviations) of 1.17 ± 0.21 and 3.47 ± 1.14 μg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.
AB - The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (± standard deviations) of 1.17 ± 0.21 and 3.47 ± 1.14 μg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.
UR - http://www.scopus.com/inward/record.url?scp=0030784668&partnerID=8YFLogxK
U2 - 10.1128/aac.41.12.2797
DO - 10.1128/aac.41.12.2797
M3 - Comment/debate
C2 - 9420064
AN - SCOPUS:0030784668
SN - 0066-4804
VL - 41
SP - 2797
EP - 2799
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 12
ER -